CPT1A and cancer: The pharmacological inhibition of the CPT-1 enzyme, which allows the entry of long-chain fatty acids into mitochondria for oxidation, has been identified as an approach for decreasing the cancer cell proliferation in prostate cancer [68], human leukaemia cells [69], triple-negative breast cancer [70] and glioma [71].